Market Overview: A Day of "Sell the News" in TechThe U.S. stock market experienced a volatile session on Thursday, February 26, 2026, as investors grappled with a "buy the rumor, sell the news" reaction to blockbuster earnings from the world’s most valuable company. Despite reporting record-breaking revenue and a stellar outlook, Nvidia (NVDA) saw its shares tumble, dragging the tech-heavy Nasdaq Composite lower and creating a ripple effect across the semiconductor and artificial intelligence sectors.As of ...

Walmart is set to pay about $16 million to Spark drivers as part of a larger settlement over claims that it misled workers about pay and tips. The Federal Trade Commission said on Thursday that Walmart agreed to a $100 million settlement over claims that the big-box retailer told Spark drivers they would earn more in base pay than they actually did. The FTC also said Walmart misled drivers "by falsely claiming that 100% of customer tips would actually go to drivers."Part of the proposed settlement includes ...

Key Takeaways UnitedHealth leverages insurance and Optum services as Q4 2025 revenues climbed 12.3% year over year.UNH's medical care ratio hit 92.4% as costs jumped, while Medicare Advantage membership rose 7.6%.Humana's Q4 revenues grew 11.3%, but 2026 EPS is seen falling 41% amid Medicare Advantage exposure.The landscape of managed care is undergoing significant changes due to rising medical utilization, evolving reimbursement models and ongoing cost challenges. Meanwhile, the aging population and the ch ...

Key Takeaways Enterprise Products Partners outpaces ET with stronger ROE and lower debt.Energy Transfer trades at 10.04X EV/EBITDA and saw 2026 earnings estimates rise 1.30%.EPD offers a 6.12% yield with steady growth and better 6-month share price gains.The companies operating in the Zacks Oil and Gas – Production Pipeline industry play a critical role in the energy ecosystem by enabling the efficient transportation of crude oil and natural gas to meet growing demand across transportation, industrial opera ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1] - The company has a market capitalization of approximately $11 million and has experienced significant stock price fluctuations, with a yearly high of $1.53 and a low of $0.22 [4][5] Stock Performance - H.C. Wainwright maintained a "Buy" rating for FibroBiologics, with the stock priced at approximately $0.26, despite a recent decrease of 1.57% [2][5] - The stock has shown volatility, fluctuating between $0.25 and $0.28 on the day of the report [2] Upcoming Events - FibroBiologics is scheduled to present at the BIO Investment & Growth Summit on March 2-3, 2026, which may enhance the company's exposure and networking opportunities [3][5]

The Democratic Republic of the Congo (DRC) has long been viewed as a frontier mining jurisdiction, one characterized by both high risk and high reward, though also one often misunderstood by international investors. Drawing on years of experience with mining in the DRC, Avanti Gold Corp (TSX-V:AGC) Acting Chief Executive Officer Mohamed Cisse understands the opportunity inherent in the country’s mineral wealth in a way few others can. Cisse played an important role in the development of Kibali, a combinatio ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

The Pioneer Of Seeking Alpha's BAD BEAT Investing, Quad 7 Capital is a team of 7 analysts with a wide range of experience sharing investment opportunities for nearly 12 years. They are best known for their February 2020 call to sell everything & go short, & have been on average 95% long 5% short since May 2020. The broader company has expertise in business, policy, economics, mathematics, game theory, & the sciences. They share both long & short trades & invest personally in equities they discuss within the ...

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e. buying assets at a discount e.g. net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e. buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get starte ...